Maria E. Goossens
Research Subjects
Maria E. Goossens has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Pieter Pannus
Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium
28 shared publications - Kevin K. Arien
Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
27 shared publications - Peter A. van Dam
Multidisciplinary Oncologic Center, Antwerp University Hospital, Edegem, Belgium
25 shared publications - Timon Vandamme
Department of Oncology Antwerp University Hospital Edegem Belgium
25 shared publications - Yana Debie
Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium
25 shared publications - Annelies Janssens
Department of Thoracic Oncology, Antwerp University Hospital, Antwerp, Belgium
24 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 3: Gating strategy for a representative sample
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 3: Gating strategy for a representative sample
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 4: Spike-specific CD4+ T cell responses post homologous or heterologous booster vaccination in subcohorts.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 4: Spike-specific CD4+ T cell responses post homologous or heterologous booster vaccination in subcohorts.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 2: Virus neutralization test with 50% neutralization titers (NT50) defined as the sample dilution (reciprocal titer) conveying 50% neutralization in SARS-CoV-2 (strains 2019-nCoV-Italy-INMI1 and VLD20211207) infected wells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 2: Virus neutralization test with 50% neutralization titers (NT50) defined as the sample dilution (reciprocal titer) conveying 50% neutralization in SARS-CoV-2 (strains 2019-nCoV-Italy-INMI1 and VLD20211207) infected wells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 1: Correlation betweenSARS-CoV-2 anti-S1 IgG antibody titers and NT50 values against Wuhan and BA.1 Omicron strains post homologous or heterologous booster vaccination in cancer patients and healthy individuals.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 1: Correlation betweenSARS-CoV-2 anti-S1 IgG antibody titers and NT50 values against Wuhan and BA.1 Omicron strains post homologous or heterologous booster vaccination in cancer patients and healthy individuals.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 6: Correlation between CD4+ and CD8+ T cell responses and SARS-CoV-2 binding antibodies post homologous or heterologous booster vaccination in cancer patients.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 6: Correlation between CD4+ and CD8+ T cell responses and SARS-CoV-2 binding antibodies post homologous or heterologous booster vaccination in cancer patients.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 5: Spike-specific CD8+ T cell responses post homologous or heterologous booster vaccination in subcohorts.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Supplementary Figure 5: Spike-specific CD8+ T cell responses post homologous or heterologous booster vaccination in subcohorts.